The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. 1991

P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
Department of Pharmacy, University of Manchester, UK.

The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally. The initial plasma half-life of pamidronate was short (42 +/- 27 min) and the apparent total plasma clearance was high (471 +/- 298 ml/min). The renal clearance (74 +/- 34 ml/min) was similar to the creatinine clearance (66 +/- 19 ml/min). Most of the renal elimination occurred during and immediately post a 4 h infusion of the drug (23.2 +/- 7.9% in 24 h). The non-renal clearance was ascribed to uptake by bone and deep tissue compartments. Little additional drug appeared in the urine after 24 h. The mean bioavailability was estimated using a parallel study design to be 0.3% for a 300 mg oral dose.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077268 Pamidronate An aminobisphosphonate that inhibits BONE RESORPTION and is used for the treatment of osteolytic lesions, bone pain, and severe HYPERCALCEMIA associated with malignancies. (3-Amino-1-hydroxypropylidene)-1,1-biphosphonate,1-Hydroxy-3-aminopropane-1,1-diphosphonic acid,AHPrBP,Amidronate,Amino-1-hydroxypropane-1,1-diphosphonate,Aminohydroxypropylidene Diphosphonate,Aminopropanehydroxydiphosphonate,Aredia,Pamidronate Calcium,Pamidronate Disodium,Pamidronate Monosodium,Pamidronic Acid,1 Hydroxy 3 aminopropane 1,1 diphosphonic acid,Amino 1 hydroxypropane 1,1 diphosphonate
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
March 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
September 1996, British journal of clinical practice. Supplement,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
January 2002, Magyar onkologia,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
January 1991, European journal of cancer (Oxford, England : 1990),
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
May 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
October 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
October 1993, Tumori,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
November 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
May 1992, Journal of the National Cancer Institute,
P T Daley-Yates, and D J Dodwell, and M Pongchaidecha, and R E Coleman, and A Howell
December 1994, Cancer,
Copied contents to your clipboard!